Crucial US Advisory Committee to Decide on Changing Infant Hepatitis B Vaccine Guideline
Following a hold-up and a particularly heated session, a federal vaccine advisory panel was scheduled to decide on Friday on whether to change the enduring advisory that each baby be inoculated against hepatitis B.
Heated Debate and a Deferred Vote
The opening session of the meeting on Thursday was characterized by intense argument over restricting access to the hepatitis B vaccine for babies and a choice to delay the ballot by a day to provide committee members extra time to review the wording. The panel, which advises the national health agency on vaccination protocols, had twice before postponed.
“Is there any definitive data of harm of giving this immunization before 30 days? Or is this theory?” inquired one adviser.
In reply, another member stated, “There is scant proof about the enduring danger.”
Existing Recommendations and Possible Consequences
The shot is currently recommended for all infants within 24 hours of being born to stop transmission of hepatitis B, which can cause serious liver damage. It has been provided to over a billion individuals for over thirty years.
The Atlanta conference presented no fresh data of harms caused by the vaccine. Authorities state any change to the existing hepatitis B immunization timeline could have significant and far-reaching repercussions for pediatric well-being in the United States.
Panel Composition and Latest Shifts
The expert committee can only offer guidance to the director of the CDC. The panel's membership has seen shifts this week, with the announcement that the group's former head would depart for an official role and be succeeded by a cardiologist who has been questioning of other vaccines.
The committee includes a number of vaccine skeptics who are in agreement with a desire to overhaul – and possibly, in some cases, eliminate – longstanding immunization guidelines.
